CymaxTM Human IL-9 ELISA Kit
- Known as:
- CymaxTM Human Interleukin-9 Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- LF-EK0281
- Product Quantity:
- 1
- Category:
- Elisa Kits
- Supplier:
- Abfron
- Gene target:
- CymaxTM Human IL-9 ELISA Kit
Related genes to: CymaxTM Human IL-9 ELISA Kit
- Gene:
- IL9 NIH gene
- Name:
- interleukin 9
- Previous symbol:
- -
- Synonyms:
- IL-9, HP40, P40
- Chromosome:
- 5q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 1990-06-11
- Date modifiied:
- 2016-10-05
Related products to: CymaxTM Human IL-9 ELISA Kit
Related articles to: CymaxTM Human IL-9 ELISA Kit
- Inflammation at the superior airway level has multiple manifestations, and allergic rhinitis and chronic rhinosinusitis with or without polyps are two of the most frequent and troublesome of them, with innate and adaptive immunity being implicated. Dendritic cells, epithelial cells, neutrophils, macrophages, mucosal mast cells, eosinophils, basophils, innate lymphoid cells (ILCs), and NK cells are the players in innate immunity, while regulatory T (Treg), TH1, TH2, TH17, T follicular helper, and B cells are components of the adaptative immune system. Th9 cells, a subset of T helper cells discovered in 2008 that produce interleukin-9 (IL-9), play a vital role in the adaptive immune response and have advantageous and harmful effects in different diseases due to the induction pattern. We queried international databases for current, up-to-date information regarding the interplay between interleukin 9 (IL-9) and helper T cells (especially Th9 cells), and by other immune cells. Interleukin-9 has multiple immunological functions, acting on various target cells through its specific receptor (IL-9R), such as the following: the regulation of allergic (Th2-type) immune responses; effects on epithelial and mucosal cells, mast cells, and eosinophils; chronic inflammation; and autoimmunity. Thus, there is a further need to translate laboratory findings into clinical practice regarding IL-9. - Source: PubMed
Publication date: 2026/04/30
Dumitru MihaiBerghi OvidiuMusat GabrielaSerboiu CrengutaOancea AlinaBerghi Alina GabrielaZamfir-Chiru-Anton AdinaVrinceanu Daniela - Trigeminal neuralgia (TN) is a debilitating neuropathic pain disorder traditionally attributed to neurovascular compression; however, this mechanism does not fully explain the marked clinical heterogeneity or persistent pain observed in a subset of patients. Increasing evidence suggests that central neuroinflammatory processes contribute to neuropathic pain, but immune profiles in the cerebrospinal fluid (CSF) and serum of patients with TN remain poorly characterized. - Source: PubMed
Publication date: 2026/05/08
Liu HongLiu Zi-WeiZhang Jiang-TaoWang Xue-LongChen Li-HuaJin Xiao-HongLiu TongJi Fu-Hai - Sepsis-associated acute kidney injury (septic AKI) is a leading cause of mortality in critically ill patients. Despite its high prevalence, no specific therapies are currently available, primarily because the molecular mechanisms that sustain renal inflammation and tubular damage remain poorly understood. - Source: PubMed
Publication date: 2026/05/22
Li ZhengWang JuanZhang LeiLiu Zhiwen - Innate lymphoid cells (ILCs) are emerging as critical modulators of inflammation in rheumatoid arthritis, contributing to both disease pathology and resolution. Group 3 ILCs (ILC3s) mirror T17 cells in their production of IL-17A and IL-22, promoting fibroblast activation, neutrophil recruitment and synovial inflammatory cascades. By contrast, group 2 ILCs (ILC2s) engage reparative and immunoregulatory pathways via secretion of IL-9, IL-13 and IL-10. Lymphoid tissue inducer (LTi) ILCs contribute to ectopic lymphoid tissue neogenesis and stromal remodelling in early disease. Clinically, alterations in ILC subset composition correlate with disease activity, therapeutic responsiveness and inflammatory burden. Advances in high-dimensional immunophenotyping, spatial transcriptomics and single-cell multi-omics now enable precise mapping of ILC subsets and their effector programmes across peripheral blood and synovial tissue, supporting their use in biomarker discovery and treatment pipelines. Furthermore, modulation of ILCs by targeting upstream cytokines, signalling pathways or the use of microbiota-derived metabolites is a potential therapeutic strategy. Finally, cell-based avenues include IL-10-producing ILC2s (ILC2) and engineered chimeric antigen receptor (CAR)-ILC2s for targeted, tissue-resident immune modulation. Although still in the preclinical stages, these approaches highlight the translational potential of ILCs as biomarkers and therapeutic targets in rheumatoid arthritis. - Source: PubMed
Publication date: 2026/05/11
Kabil Ahmed KKuo I-ChihColonna MarcoMcNagny Kelly M - Fluid protein studies in cerebrospinal fluid (CSF) and plasma have provided important insights into neurodegenerative dementias; however, there is a limited investigation of sex-related differences and cross-biofluid relationships. In Alzheimer's disease (AD), Lewy body dementia (LBD), and frontotemporal dementia (FTD), large-scale, sex-stratified analyses of paired CSF and plasma samples remain scarce. Using the multiplex and ultrasensitive capabilities of NULISAseq™ technology, this study aims to characterize sex- and disease-specific proteomic alterations associated with Central Nervous System (CNS) pathology to explore underlying mechanisms. - Source: PubMed
Publication date: 2026/05/08
Comas-Albertí AinaLladó AlbertEsteller-Gauxax DianaBorrego-Écija SergiFalgàs NeusDakterzada FaridaPérez-Millan AgnèsPuey RogerCollet-Romà TàniaGuillén NúriaMassons MiquelTort-Merino AdriàAugé Josep MariaFernandez-Villullas GuadalupeBosch BeaRuiz-García RaquelNaranjo LauraBalasa MirceaPiñol-Ripoll GerardAntonell AnnaSánchez-Valle Raquel